Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors
Conditions
Interventions
ADCT-901
Locations
13
United States
Sarah Cannon at HealthONE
Denver, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Emory University, Winship Cancer Institute
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
University Hospitals of Cleveland Medical Center (UHCMC)
Cleveland, Ohio, United States
Sarah Cannon at University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Start Date
September 9, 2021
Primary Completion Date
September 13, 2024
Completion Date
September 13, 2024
Last Updated
May 22, 2025
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
ADC Therapeutics S.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions